New vaccine platform

Subunit vaccines with intrinsic adjuvancy, overcoming drawbacks of inactivated or attenuated vaccines.

Our platform allows the production of Microspheres (400 - 4000 nm) loaded with the proteins of interest, made in any expression system (mammalian, baculovirus, bacteria).

Concept demonstrated in animal healthcare. Recombinant vaccine incorporating Bluetongue (BTV) or African Horse Sickness viruses epitopes has generated significant levels of neutralizing antibodies, protecting mice towards a lethal challenge.

• Vaccines 2022, 10(7), 1124 https://doi.org/10.3390/vaccines10071124

• Vaccine, 2020, 38, 882-889 https://doi.org/10.1016/j.vaccine.2019.10.087

• Antiviral Research, 2017, 142, 55 http://dx.doi.org/10.1016/j.antiviral.2017.03.010

SARS-COV-2 vaccine project funded by European Vaccine Initiative (EVI) and Spanish funds.